Skip to content
Condition Guide

Best Peptides for Fertility & Reproductive Health — Evidence-Based Guide (2026)

A comprehensive guide to the best peptides for fertility and reproductive health in both men and women. Covers kisspeptin (GnRH trigger), PT-141/bremelanotide for female sexual dysfunction, BPC-157 endometrial and testicular data, and GH secretagogues for ovarian reserve.

Quick Answer

The most researched peptides for fertility include kisspeptin-54, which triggers the LH surge used clinically to replace hCG in IVF protocols, reducing ovarian hyperstimulation risk. PT-141 (bremelanotide) is FDA-approved for hypoactive sexual desire disorder in women. BPC-157 shows endometrial healing and testicular protection data. Ipamorelin supports ovarian reserve through GH/IGF-1 pathways.

Overview

Fertility disorders affect 15–20% of couples and involve complex hormonal, structural, and metabolic dysfunctions. Peptides increasingly appear in reproductive medicine — both in established clinical protocols and emerging research. Kisspeptin is the most clinically advanced, having replaced hCG as an LH-surge trigger in IVF cycles at several centres due to its dramatically lower risk of ovarian hyperstimulation syndrome (OHSS). PT-141 (bremelanotide) received FDA approval for female hypoactive sexual desire disorder, addressing the sexual dysfunction that often accompanies fertility challenges. BPC-157 has demonstrated endometrial healing properties relevant to implantation failure and testicular protection against toxic damage in animal models. Growth hormone secretagogues (ipamorelin) support ovarian reserve and embryo quality by augmenting GH/IGF-1 signalling in follicular development. These peptides represent a growing interface between traditional reproductive endocrinology and peptide pharmacology.

Best Peptides for Fertility & Reproductive Health

Kisspeptin-54high efficacy

Mechanism: Endogenous neuropeptide that binds KISS1R on GnRH neurons to trigger the hypothalamic GnRH pulse that drives pituitary LH and FSH release — the master regulator of the reproductive HPG axis; used to trigger the LH surge in IVF without direct gonadotropin receptor stimulation

Key benefit: Clinical trials at Kings College London showed equivalent IVF outcomes to standard hCG trigger with near-zero OHSS incidence — a paradigm shift for high-risk IVF patients with polycystic ovaries

Kisspeptin-10moderate efficacy

Mechanism: C-terminal decapeptide fragment of kisspeptin with potent KISS1R agonism; activates GnRH secretion and has shorter half-life than kisspeptin-54, useful for diagnostic assessment of HPG axis function

Key benefit: Used diagnostically to assess hypothalamic reserve and for research into GnRH pulse frequency disorders underlying hypothalamic amenorrhoea and hypogonadotropic hypogonadism

PT-141high efficacy

Mechanism: Melanocortin receptor agonist (MC1R/MC4R) that activates central dopaminergic pathways driving sexual motivation and arousal in both sexes, independent of vascular mechanisms — works through the brain rather than through genital blood flow

Key benefit: FDA-approved as bremelanotide (Vyleesi) for hypoactive sexual desire disorder in premenopausal women — the first centrally-acting peptide approved for female sexual dysfunction, addressing libido as a component of fertility challenge

BPC-157emerging efficacy

Mechanism: Promotes angiogenesis and tissue repair in endometrial tissue, protects testicular and ovarian tissue from ischemia and toxic injury, modulates NO pathways relevant to uterine receptivity, and reduces inflammatory signalling that impairs implantation

Key benefit: Preclinical data shows protection against testicular torsion-induced damage and improvement in endometrial vascularisation relevant to recurrent implantation failure — emerging adjunct for unexplained fertility issues

Ipamorelinemerging efficacy

Mechanism: Selective GHRP that increases GH and IGF-1, which are critical for follicular development, oocyte quality, endometrial receptivity, and spermatogenesis — IGF-1 receptors are expressed on both granulosa cells and Sertoli cells

Key benefit: Used adjunctively in poor ovarian responders to IVF — GH supplementation during ovarian stimulation has meta-analytic evidence for improved clinical pregnancy rates in poor responders

Quick Comparison

PeptideEfficacyKey BenefitProfile
Kisspeptin-54highClinical trials at Kings College London showed equivalent IVF outcomes to standard hCG trigger with near-zero OHSS incidence — a paradigm shift for high-risk IVF patients with polycystic ovariesView →
Kisspeptin-10moderateUsed diagnostically to assess hypothalamic reserve and for research into GnRH pulse frequency disorders underlying hypothalamic amenorrhoea and hypogonadotropic hypogonadismView →
PT-141highFDA-approved as bremelanotide (Vyleesi) for hypoactive sexual desire disorder in premenopausal women — the first centrally-acting peptide approved for female sexual dysfunction, addressing libido as a component of fertility challengeView →
BPC-157emergingPreclinical data shows protection against testicular torsion-induced damage and improvement in endometrial vascularisation relevant to recurrent implantation failure — emerging adjunct for unexplained fertility issuesView →
IpamorelinemergingUsed adjunctively in poor ovarian responders to IVF — GH supplementation during ovarian stimulation has meta-analytic evidence for improved clinical pregnancy rates in poor respondersView →

References

  1. Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilisation (2014) — PubMed
  2. Bremelanotide for hypoactive sexual desire disorder: the RECONNECT studies (2019) — PubMed
  3. Growth hormone co-treatment within IVF: a systematic review and meta-analysis (2013) — PubMed

Frequently Asked Questions

How is kisspeptin used in IVF treatment?
In conventional IVF, the final oocyte maturation trigger uses human chorionic gonadotropin (hCG), which directly activates FSH/LH receptors and carries a 1–2% risk of severe ovarian hyperstimulation syndrome (OHSS) in high-risk patients. Kisspeptin-54 works differently — it triggers the endogenous hypothalamic LH surge rather than directly activating ovarian receptors. Kings College London published landmark trials showing equivalent live birth rates with kisspeptin-54 trigger versus hCG, with dramatically reduced OHSS incidence. It is now offered at specialist fertility centres particularly for PCOS patients at high OHSS risk.
Is PT-141/bremelanotide safe for women trying to conceive?
PT-141 (bremelanotide/Vyleesi) is FDA-approved for premenopausal women with acquired hypoactive sexual desire disorder, but it carries a specific contraindication in pregnancy — it has caused fetal harm in animal studies. Women actively trying to conceive should use effective contraception during PT-141 use and stop at least one week before attempting conception. It is not intended to be used concurrently with conception attempts but rather to address libido issues during the period when couples are working on fertility. Any use in the fertility context should be under explicit guidance from both a prescribing clinician and the treating reproductive endocrinologist.
Can growth hormone peptides improve egg quality?
This is an active area of clinical research. GH and IGF-1 receptors are expressed on granulosa cells and oocytes, and GH signalling influences follicular development, oocyte maturation, mitochondrial function within oocytes, and endometrial receptivity. Multiple small RCTs and meta-analyses of GH co-treatment in IVF for poor ovarian responders (usually defined as women producing <3 oocytes) show modest but consistent improvements in oocyte yield, fertilisation rates, and clinical pregnancy rates. GH secretagogues (ipamorelin, sermorelin) are used off-label to achieve similar GH augmentation at lower cost and with oral/subcutaneous administration rather than recombinant GH injection.
Are there peptides to improve sperm quality or male fertility?
Several peptides have preclinical relevance to male fertility. BPC-157 has demonstrated protection against testicular torsion injury and chemotherapy-induced testicular damage in animal models, which could be relevant for male fertility preservation. Kisspeptin signalling is critical for the pulsatile LH release that drives testosterone production and spermatogenesis — kisspeptin is being studied as a treatment for hypogonadotropic hypogonadism. Gonadorelin (GnRH) is used clinically in men with hypothalamic hypogonadism to restore spermatogenesis. Growth hormone secretagogues support testosterone biosynthesis indirectly through IGF-1 signalling on Leydig cells.
What is the role of BPC-157 in endometrial health?
The endometrium (uterine lining) must reach adequate thickness (>7mm) and develop appropriate vascularity and receptivity markers for successful embryo implantation. BPC-157 promotes angiogenesis through VEGF upregulation, which could theoretically improve endometrial blood flow and thickness. In animal models of uterine injury, BPC-157 demonstrated accelerated healing of endometrial tissue. For women with thin endometrium or recurrent implantation failure of suspected endometrial origin, BPC-157 is used off-label as an adjunct, though human RCT data is currently lacking. Research is actively ongoing in this area.

Explore next

Related peptides